- To be established within the Hwasun Vaccine Industry Special Zone in Jeollanamdo...aiming for 900 graduates by 2026

- Received a total of 24 billion won in government funding over four years starting from 2023 for the construction of the training center

▲    Manpower Training Center Building Rendering

PCMO (Director Min Cho, hereinafter referred to as the Center) announced on the 3rd that it has commenced construction of an educational facility aimed at fostering bio specialized workforce with a target completion date of May 2025 within the Hwaseong Vaccine Industry Special Zone in Jeollanamdo.

The facility is designed to have a total floor area of 2,794 ㎡ across two floors above ground, featuring laboratories where students can directly engage in production and quality control testing, as well as residential facilities (including dormitories) for medium- to long-term training lasting more than two weeks. A total of 24 billion won in funding, supported by the Ministry of Trade, Industry and Energy and Jeollanamdo, is planned to be invested.

The Center aims to produce a total of 900 graduates by 2026 through internal facilities and education utilizing VR (Virtual Reality), aiming to address the shortage of field personnel demanded by the recent government and bio industries.

According to feedback from graduates of the Center's education programs, they expressed satisfaction in gaining relative merits in job seeking activities through firsthand experiences, practical know-how, and field experiences that cannot be learned in school. Among the students who completed their education in 2023, some have reported being employed in various bio companies, with expectations for an increase in employment rates of graduates starting from this year as the business becomes more active.

This project is based on the trust built by the Ministry of Trade, Industry and Energy and Jeollanamdo, stemming from achievements in projects such as the establishment of PCMO as part of the Vaccine Global Industry Establishment Project since 2017 and the production of COVID-19 clinical trial samples.

Additionally, the Center is actively engaged in operations such as signing agreements with companies like Samsung Biologics and Celltrion to achieve the Ministry of Trade, Industry and Energy's 'Bio-Manufacturing Innovation Strategy'. With the bio industry being evaluated as one of the future growth engines, the Center's future activities are highly anticipated.